

## **Yangchao CHEN**

### **Present Appointment**

Professor, School of Biomedical Sciences, Faculty of Medicine, Chinese University of Hong Kong

### **Academic Qualification**

- 02. 2005 Postdoctoral Fellow, University of Washington, Seattle, USA
- 07. 2003 PhD in Biochemistry, Sun Yat-Sen University, China
- 07. 2000 MPhil, Guangdong Medical College, China
- 07.1997 Hunan Medical University, China

### **Employment History**

- 08, 2021— Professor, School of Biomedical Sciences, CUHK
- 06, 2015— 07.2021 Associate Professor, School of Biomedical Sciences, CUHK
- 04, 2010—05, 2015 Assistant Professor, School of Biomedical Sciences, CUHK
- 04, 2009—04, 2010 Assistant Professor, Department of Medicine & Therapeutics, CUHK
- 04. 2007—04, 2009 Research Assistant Professor  
Department of Medicine & Therapeutics, CUHK

### **Awards and Distinctions**

- 1. The recipient of a grant amounting to 100,000 US dollars in the second round of Grand Challenges Explorations in 2009 from The Bill & Melinda Gates Foundation. One of the 81 receipts out of more than 3,000 applicants worldwide including North America and Europe
- 2. Young Investigator Award, American Pancreatic Association & International Association of Pancreatology, October 2012
- 3. Young Investigator Award, International Digestive Diseases Forum, June 2013
- 4. Collaborative Research Award, The Chinese University of Hong Kong, August 2014
- 5. Young Investigator Award, Japanese Cancer Association Annual Meeting, September 2014
- 6. Outstanding Young Investigator Award, Pancreatic Cancer Committee, Chinese Anti-cancer Association, July 2016
- 7. The First Place of Paper Award, The Chinese Translational Medicine Association 2016 Conference, October 2016
- 8. Young Investigator Award, American Association for Cancer Research (AACR)-Korean Cancer Association (KCA) joint conference on Precision Medicine in Solid Tumors, November 2018
- 9. The Best of the AACR Journals 2022 & Most-Cited Article published in 2020 Cancer Research, American Association for Cancer Research, April 2022.

### **Professional Affiliations**

- 2003— Member, American Association for Cancer Research (AACR)
- 2007— Member, Chinese Association of Pharmaceutical Scientists, USA (CAPS-USA)
- 2007— Member, The Consortium for Globalization of Chinese Medicine Foundation
- 2007— Member, The Society of Hong Kong Scholars
- 2012— Member, European Association for Predictive, Preventive and

Personalised Medicine (EPMA)  
 2012— National EPMA Board Member of China  
 2012— Member, American Pancreatic Association  
 2012— Member, International Association of Pancreatology

### **Academic Service**

Grant reviewer:

2018— World Cancer Research Fund  
 2017— Science and Technology Development Fund of Macau  
 2016— National Science Foundation of Poland  
 2015— European Science Foundation  
 2015— Italian Ministry of Health  
 2015— University of Macau  
 2012— National Natural Science Foundation of China (NSFC)  
 2011— Shenzhen Research Foundation

### **Editor in Chief**

2019— *Current Cancer Therapy Reviews* (indexed in Emerging SCI)

### **Editorial board member**

2020— *International Journal of Biological Sciences* (impact fact 10.9)  
 2014— *World Journal of Gastroenterology* (impact fact 5.6)  
 2020— *Biosensors* (impact fact 3.2)  
 2010— *Journal of Chinese Clinical Medicine*  
 2011— *American Journal of Molecular Biology*  
 2013— *Journal of Life Medicine*  
 2013— *Journal of Metabolomics and Systems Biology*  
 2013— *Journal of Gene Therapy*  
 2013— *Molecular Biology and Genetic Engineering*  
 2014— *Quality Control Expert, Chinese academic journals (CD) "electronic magazine" China National Knowledge Infrastructure*  
 2013— *Pharmacologia*  
 2016— *Epigenomics and Epigenetics*  
*Ad hoc* Reviewer for *Gut, Cancer Research, Mol Therapy, Oncogene, Cancer Letters, PLoS One, Life Science, European Journal of Surgical Research, BBA-Proteins & Proteomics, Pharmaceutical Res, Anti-cancer Drugs, BMC Medical Genomics, Electrophoresis, Int J Biochem Cell Biol, Tumor Biology.*

### **MAIN RESEARCH INTERESTS**

- ▶ RNA biomarkers for early diagnosis of cancer
- ▶ Identification and characterization of long and short non-coding RNAs with critic roles in cancer
- ▶ RNA therapeutics for cancer

### **Research Grants with Capacity as PI**

1. Development of mRNA vaccine targeting tumor immune microenvironment for mesothelioma treatment. Pneumoconiosis Compensation Fund Board, 2024-2026, HK\$ 2,696,080, Capacity: PI.
2. Development of Liquid Biopsy Assays Based on Exosomal Small Non-coding RNAs for Non-invasive Early Detection of Pancreatic Cancer. Research Impact Fund,

- 2024-2029, HK\$: 8,000,000, Capacity: PI.
3. Exploration on the Novel Gene Regulatory Mechanisms and Diagnostic Potential of Circular RNAs in Pancreatic Ductal Adenocarcinoma. Strategic Seed Funding for Collaborative Research Scheme, CUHK, 2024-2026, HK\$ 500,000, Capacity: PI.
  4. To elucidate the novel DNA interacting mechanism of oncogenic circular RNA circFOXK2, National Natural Science Foundation of China (NSFC), 2023-2026, RMB: 540,000, Capacity: PI.
  5. Ribonucleic Acid Biomarkers for early diagnosis of cancer. Research Matching Grant Scheme, UGC, 2021-2026, HK\$: 1,750,000, Capacity: PI.
  6. RNA Biomarkers for early diagnosis of cancer. Donation, 2021-2026, HK\$: 3,700,000, Capacity: PI.
  7. Development of a modified droplet digital PCR (ddPCR) assay for highly accurate and sensitive detection of SARS-CoV-2 RNA for screening of infected individuals and environmental monitoring. Worldwide Universities Network Special Grant Scheme, 2020-2021, GBP:10,000, Capacity: PI.
  8. Characterization of the anti-metastatic function of POU4F3 in pancreatic ductal adenocarcinoma and delineate its underlying mechanism. Research Grants Council General Research Fund (GRF), 2020-2023, HK\$: 953,013, Capacity: PI.
  9. Characterization of the novel KRAS-driven STK32B kinase and identification of selective inhibitors for therapeutic intervention in pancreatic cancer. Research Grants Council General Research Fund (GRF), 2019-2022, HK\$: 868,956, Capacity: PI.
  10. Genome-wide identification of circular RNAs with critical roles in pancreatic ductal adenocarcinoma. Research Grants Council General Research Fund (GRF), 2018-2021, HK\$: 1,225,785, Capacity: PI.
  11. Investigation of the cell free DNAs and exosome in serum samples of HCC patients treated with Pianzaihuan. Guangzhou Evidence-based Medicine Tech. Co. Ltd., 2017-2019. HK\$:1,159,000. Capacity: PI.
  12. Identification of novel tumor suppressor long non-coding RNAs epigenetically silenced in hepatocellular carcinoma. Research Grants Council General Research Fund (GRF), 2017-2020, HK\$: 1,000,716, Capacity: PI.
  13. Metabolism and pharmacokinetic analysis of a small molecule modulator of tumor suppressor microRNA-34a. Innovation and Technology Fund, 2015-2017, HK\$: 1,398,664. Capacity: PI.
  14. Characterization of a novel long non-coding RNA AK311005 with potential tumor suppressive role in pancreatic ductal adenocarcinoma. Research Grants Council General Research Fund (GRF), 2015-2018, HK\$: 763,494, Capacity: PI.
  15. Identification and functional characterization of long non-coding RNAs associated with pancreatic ductal adenocarcinoma. Research Grants Council General Research Fund (GRF), 2014-2017, HK\$: 1,299,049, Capacity: PI.
  16. Regulation and function of histone demethylase JMJD3 in HBV-induced hepatocarcinogenesis. Health and Medical Research Fund (HMRF), 2013-2015, HK\$: 780,128, Capacity: PI.
  17. Functional characterization of EZH2/miR-218 interaction in pancreatic ductal adenocarcinoma. Research Grants Council General Research Fund (GRF), 2012-2015, HK\$: 862,500, Capacity: PI.
  18. Identification of novel therapeutic targets for pancreatic cancer by genome-wide RNAi screening in vivo. National Natural Science Foundation of China (NSFC), 2017-2020, RMB: 570,000, Capacity: PI.
  19. Investigation on the anti-cancer activity against liver cancer and the underlying

- mechanism of small molecule modulator of microRNA-34a. National Natural Science Foundation of China (NSFC), 2015-2019, RMB: 760,000, Capacity: PI.
20. Role of microRNAs in the multiple target efficacy of berberine. Institute of Materia Medica, Peking Union Medical College, 2015-2017, RMB: 300,000, Capacity: PI.
  21. Functional characterization of Hepatitis B viral X protein/microRNA-21 interaction in HBV associated hepatocellular carcinoma. Research Fund for the Control of Infectious Disease, 2012-2014, HK\$: 1,000,000, Capacity: PI.
  22. The mechanism of polycomb protein EZH2 silencing on microRNA-34a in pancreatic cancer and its significance in tumorigenesis, National Natural Science Foundation of China (NSFC), 2012-2015, RMB: 260,000, Capacity: PI.
  23. Functional characterization of EZH2/miR34a interaction in cancer. Shenzhen Municipal Basic Research Program, 2012-2014, RMB: 100,000, Capacity: PI.
  24. Generation of Influenza-resistant chicken by triple combination lentiviral vector-mediated genetic modification. Grand Challenges Explorations No. 53011, Bill & Melinda Gates Foundation. 2009-2011, US\$: 100,000, Capacity: PI.
  25. Regulation of S100P expression by IL-6 in pancreatic ductal adenocarcinoma. Research Grants Council General Research Fund (GRF), 2009-2012, HK\$: 977,765, Capacity: PI.
  26. Triple combination lentiviral vector-based hematopoietic stem cell gene therapy for inhibition of drug resistant HIV-1, Research Fund for the Control of Infectious Disease, 2009-2011, HK\$: 800,000, Capacity: PI.
  27. Development of HPV therapeutic vaccine and related immunotherapy for treating cervical cancer, Innovation and Technology Fund, 2008-2010, HK\$: 1,571,682, Capacity: PI.
  28. Development of HPV therapeutic vaccine. HealthBaby Biotech (Hong Kong) Co., Ltd. 2008-2010, HK\$: 1,571,682, Capacity: PI.

### **Publications (\*corresponding author)**

1. Liu Y, Tang SC, Li CH, To KF, Li B, Chan SL, Wong CH, **Chen Y**. The molecular mechanism underlying KRAS regulation on STK31 expression in pancreatic ductal adenocarcinoma. *Cancer Sci*. 2024 Oct;115(10):3288-3304.
2. Zhong HJ, Liu AQ, Huang DN, Zhou ZH, Xu SP, Wu L, Yang XP, **Chen Y**, Hong MF, Zhan YQ. Exploring the impact of gut microbiota on liver health in mice and patients with Wilson disease. *Liver Int*. 2024 Oct;44(10):2700-2713.
3. Xian G, Huang R, Xu M, Zhao H, Xu X, **Chen Y**, Ren H, Xu D, Zeng Q. Noncoding RNA regulates the expression of Krm1 and Dkk2 to synergistically affect aortic valve lesions. *Exp Mol Med*. 2024 Jul;56(7):1560-1573.
4. Ali S, Haq TU, Hussain M, Uzair M, Ali Y, **Chen Y**, Jalil F, Shah AA. Genetic variants rs2910164, rs4636297 and rs895819 may contribute to the onset of acute myocardial infarction in Pakistani population. *PLoS One*. 2024 Jan 2;19(1):e0296025.
5. Wang S, Chen J, Li P, **Chen Y\***. LINC01133 can induce acquired resistance to ferroptosis in pancreatic cancer by enhancing the mRNA stability of FSP1 through forming the LINC01133-FUS-FSP1 complex. *Cell Death Dis*. 2023 Nov 25;14(11):767.
6. Yeung SSY, Ma SL, Wang X, **Chen Y**, Tsui SKW, Tang NLS, Woo J. Telomere length among Chinese aged 75+ years. *Gerontology*. 2023 Oct 19. doi: 10.1159/000534644. Online ahead of print.
7. Chiang CY, Zhang M, Huang J, Zeng J, Chen C, Pan D, Yang H, Zhang T, Yang M, Han Q, Wang Z, Xiao T, **Chen Y**, Zou Y, Yin F, Li Z, Zhu L, Zheng D. A novel

- selective ERK1/2 inhibitor, Laxiflorin B, targets EGFR mutation subtypes in non-small-cell lung cancer. *Acta Pharmacol Sin.* 2023 Oct 10. doi: 10.1038/s41401-023-01164-w. Online ahead of print.
8. Wang JT, Wong CH, Zhu Y, Yao X, Ng KC, Zhou C, To KF, **Chen Y\***. Identification of GRIN2D as a novel therapeutic target in Pancreatic Ductal Adenocarcinoma. *Biomarker Research*, 2023, 11(1):74. doi: 10.1186/s40364-023-00514-4.
  9. Luo Z, **Chen Y\***. Unlocking Delivery Strategies for mRNA Therapeutics. *Recent Patents on Anti-Cancer Drug Discovery*, 2023 Jun 7. doi: 10.2174/1574892818666230607093231.
  10. Peña-Paladines JJ, Wong CH, **Chen Y\***. Circularized RNA as novel therapeutics in cancer. *Int J Biochem Cell Biol.* 2023 Feb 8;14(2):431.
  11. Song SL, Li B, Carvalho MR, Wang HJ, Mao DL, Wei JT, Chen W, Weng ZH, **Chen YC**, Deng CX, Reis RL, Oliveira JM, He YL, Yan LP, Zhang CH. Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends. *Pharmacol Ther.* 2022 Nov;239:108276.
  12. Li S, Qiu G, Wu J, Ying J, Deng H, Xie X, Lin X, Xie Z, Qin Y, Wang Y, Ma X, Brcic L, Provencio M, **Chen Y**, Zhou C, Liu M. Identification and validation of a ferroptosis-related prognostic risk-scoring model and key genes in small cell lung cancer. *Transl Lung Cancer Res.* 2022 Jul;11(7):1380-1393.
  13. Haq TU, Zahoor A, Ali Y, **Chen Y**, Jalil F, Shah AA. Genetic Variants of *MIR27A*, *MIR196A2* May Impact the Risk for the Onset of Coronary Artery Disease in the Pakistani Population. *Genes (Basel).* 2022 Apr 24;13(5):747.
  14. Yang W, Gao K, Qian Y, Huang Y, Xiang Q, Chen C, Chen Q, Wang Y, Fang F, He Q, Chen S, Xiong J, **Chen Y**, Xie N, Zheng D, Zhai R. A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes. *J Hematol Oncol.* 2022 May 7;15(1):53.
  15. Li L, Chen C, Xiang Q, Fan S, Xiao T, **Chen Y**, Zheng D. Transient Receptor Potential Cation Channel Subfamily V Member 1 Expression Promotes Chemoresistance in Non-Small-Cell Lung Cancer. *Front Oncol.* 2022 Mar 25;12:773654.
  16. Wong CH, Li CH, Luo Z, Tong JHM, Zheng D, He Q, Lou UK, To KF, **Chen Y\***. The Establishment of CDK9/ RNA PolII/H3K4me3/DNA Methylation Feedback Promotes HOTAIR Expression by RNA Elongation Enhancement in Cancer. *Molecular Therapy.* 2022, 30:1597-1609.
  17. Wong CH, Lou UK, Fung FKC, Tong JHM, Zhang CH, To KF, Chan SL, **Chen Y\***. CircRTN4 Promotes Pancreatic Cancer Progression through a Novel CircRNA-miRNA-lncRNA Pathway and Stabilizing Epithelial-Mesenchymal Transition Protein. *Mol Cancer*, 2022; 21(1):10.
  18. Li L, Chen C, Xiao T, **Chen Y**, Zhao Y, Zheng D. The impact of TRPV1 on cancer pathogenesis and therapy: A systematic review. *Int J Biol Sci.* 2021; 17:2034-2049.
  19. Ali Y, Khan S, **Chen Y**, Farooqi N, Islam ZU, Akhtar M, Aamir, Aman A, Shah AA, Jamal M, Jalil F. Association of *AFF3* Gene Polymorphism rs10865035 with Rheumatoid Arthritis: A Population-Based Case-Control Study on a Pakistani Cohort. *Genet Res (Camb).* 2021;2021:5544198.
  20. Liu Z, Akbar SK, Lai C, Chen H, Huang S, Xia S, Chen B, Jia H, Ji T. **Chen Y\***, Zhou Q, Detection of COVID-19: A review of the current literature and future perspective. *Biosens Bioelectron.* 2020;166:112455.
  21. Chiang C, Zhang M, Wang D, Xiao T, Zhu L, Chen K, Huang J, Huang J, Zhu J, Li L, Chen C, **Chen Y**, Hu H, Jiang W, Zou Y, Wang T, Zheng D. Therapeutic potential of targeting MKK3-p38 axis with Capsaicin for Nasopharyngeal Carcinoma. *Theranostics.* 2020;10:7906-7920.

22. Zhu YX, Li CH, Li G, Feng H, Xia T, Wong CH, Fung FKC, Tong JHM, To KF, Chen R, **Chen Y\***. LLGL1 Regulates Gemcitabine Resistance by Modulating ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma. *Cell Mol Gastroenterol Hepatol*. 2020, 10:811-828.
23. Wong CH, Lou UK, Li Y, Chan SL, Tong JHM, To KF, **Chen Y\***. CircFOXK2 Promotes Tumor Growth and Metastasis of Pancreatic Ductal Adenocarcinoma via Complexing with RNA Binding Proteins and Sponging MiR-942. *Cancer Res*. 2020;80:2139-2149.
24. Lou UK, Wong CH, **Chen Y\***. A simple and rapid colorimetric detection of serum lncRNA biomarkers for diagnosis of pancreatic cancer. *RSC Advances*. 2020, 10: 8087-8092.
25. Wong CH, Li CH, He Q, Chan SL, Tong JHM, To KF, Lin LZ, **Chen Y\***. Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma. *Cancer Lett*. 2020, 477:1-9.
26. Liu X, Zhang P, Xie C, Sham Kwy, Ng SSM, **Chen Y**, Cheng CHK. Activation of PTEN by inhibition of TRPV4 suppresses colon cancer development. *Cell Death Dis*. 2019;10:460.
27. Xu, F, Li CH, Wong CH, Chen GG, Lai PBS, Shao S, Chan SL, **Chen Y\***. Genome-wide screening and functional analysis identifies tumor suppressor long non-coding RNAs epigenetically silenced in hepatocellular carcinoma. *Cancer Res*. 2019; 79:1305-1317.
28. Wong CH, **Chen Y\***. Clinical significance of exosomes as potential biomarkers in cancer. *World J Clin Cases*. 2019; 7: 171-190.
29. Li CH, Tang SC, Wong CH, Wang Y, Jiang JD, **Chen Y\***. Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway. *Eur J Pharmacol*. 2018;825:107-118.
30. Xiao Z, **Chen Y\***. Identification of Small Molecule Modulators of MicroRNA by Library Screening. *Methods Mol Biol*. 2017;1517:169-178.
31. Li CH, Xiao Z, Tong J, To KF, Fang X, Cheng ASL, **Chen Y\***. EZH2 Coupled with HOTAIR to Silence MicroRNA-34a by the induction of heterochromatin formation in Human Pancreatic Ductal Adenocarcinoma. *Int J Cancer*. 2017, 140:120-129.
32. Feng HY, **Chen Y\***. Role of bile acids in carcinogenesis of pancreatic cancer: an old topic with new perspective. *World J Gastroenterol*. 2016;22:7463-77.
33. Ma JY, Zhou X, Fu J, He CY, Feng R, Huang M, Shou JW, Zhou ZX, Li XY, Zhang L, **Chen Y**, Wang Y. In vivo metabolite profiling of a purified Ellagitannin isolated from *Polygonum capitatum* in rats. *Molecules*. 2016, 21, 21:pii: E1110.
34. Wong CH, Li YJ, **Chen Y\***. Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancer. *World J Gastroenterol*. 2016;22: 7046-7057.
35. Lau OC, Shen B, Wong CO, Tjong YW, Lo CY, Wang HC, Huang Y, Yung WH, **Chen Y**, Fung ML, Rudd JA, Yao X. TRPC5 channels participate in pressure-sensing in aortic baroreceptors. *Nat Commun*. 2016;7:11947.
36. Li CH, **Chen Y\***. Diagnostic potential of lncRNAs in cancer. *EBioMedicine*, 2016, 7:7-8.
37. Tang W, Han M, Ruan B, Jin W, Lou J, Yuan X, Chen D, **Chen Y**, Shin VY, Jin H, Wang X. Overexpression of GOLPH3 is associated with poor survival in Non-small-cell lung cancer. *Am J Transl Res*. 2016;8:1756-62.
38. Hao Y, Chow AW, Yip WC, Li CH, Wan TF, Tong BC, Cheung KH, Chan WY, **Chen Y**, Cheng CH, Ko WH. G protein-coupled estrogen receptor inhibits the P2Y receptor-mediated Ca(2+) signaling pathway in human airway epithelia. *Pflugers Arch*. 2016;468:1489-503.

39. Siu GK, Zhou F, Yu MK, Zhang L, Wang T, Liang Y, **Chen Y**, Chan HC, Yu S. Hepatitis C virus NS5A protein cooperates with phosphatidylinositol 4-kinase III $\alpha$  to induce mitochondrial fragmentation. *Sci Rep*. 2016;6:23464.
40. Cheung RC, Ng TB, Wong JH, **Chen Y**, Chan WY. Marine natural products with anti-inflammatory activity. *Appl Microbiol Biotechnol*. 2016;100:1645-66.
41. Li XY, Zhao ZX, Huang M, Feng R, He CY, Ma C, Luo SH, Fu J, Wen BY, Ren L, Shou JW, Guo F, **Chen Y**, Gao X, Wang Y, Jiang JD. Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. *J Transl Med*. 2015;13:278.
42. Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, Fu J, Tan XS, Li XY, Wen BY, Chen X, Yang XY, Ren G, **Chen Y**, You XF, Wang Y, Jiang JD. Transforming berberine into its intestine absorbable form by gut microbiota. *Sci Rep*. 2015; 5:12155.
43. Li CH, **Chen Y\***. Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy. *Current Genomics*. 2015, 16: 319-326.
44. Zhu R, Mok MT, Kang W, Lau SS, Yip WK, **Chen Y**, Lai PB, Wong VW, To KF, Sung JJ, Cheng AS, Chan HL. Truncated HBx-dependent silencing of GAS2 promotes hepatocarcinogenesis through deregulation of cell cycle, senescence and p53-mediated apoptosis. *J Pathol*. 2015;237:38-49.
45. Li CH, **Chen Y\***. Targeting EZH2 for Cancer Therapy: Progress and Perspective. *Curr Protein Pept Sci*. 2015, 16:559-70.
46. Shen J, Xiao Z, Wu WK, Wang MH, To KF, **Chen Y**, Yang W, Li MS, Shin VV, Tong JH, Kang W, Zhang L, Li M, Wang L, Lu L, Chan RL, Wong SH, Yu J, Chan MT, Chan FK, Sung JJ, Cheng AS, Cho CH. Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis. *Cancer Res*. 2015;75:754-65.
47. Xiao Z, **Chen Y\***. Small molecule targeting miR-34a for cancer therapy, *Molecular & Cellular Oncology*. 2015;2:1, e977160.
48. Wang J, Dong L, Xu L, Chu ES, **Chen Y**, Shen J, Li X, Wong CC, Sung JJ, Yu J. B cell CLL/lymphoma 6 member B inhibits hepatocellular carcinoma metastases in vitro and in mice. *Cancer Lett*. 2014;355:192-200.
49. Xiao Z, Li CH, Chan SL, Xu F, Feng L, Wang Y, Jiang JD, Sung JJY, Cheng CHK, **Chen Y\***. A small molecule modulator of the tumor suppressor miRNA-34a inhibits the growth of hepatocellular carcinoma. *Cancer Res*. 2014;74:6236-47.
50. Li CH, Xu F, Chow SC, Feng L, Yin D, Ng TB, **Chen Y\***. Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression. *Eur J Cancer*. 2014;50:2560-9.
51. Ma JY, Zhou X, Fu J, Hu T, Or PM, Feng R, He CY, Chen WJ, Zhang X, **Chen Y\***, Wang Y, Yeung JH. Metabolite profiling analysis of FR429, an ellagitannin purified from Polygonum capitatum, in rat and human liver microsomes, cytosol and rat primary hepatocytes *in vitro*. *Chem Biol Interact*. 2014; 220:33-40.
52. He CY, Fu J, Ma JY, Feng R, Tan XS, Huang M, Shou JW, Zhao ZX, Li XY, Zhang XF, **Chen Y\***, Wang Y. Biotransformation and metabolic profile of extracts with potential anti-tumor activity from a traditional Miao-nationality herbal medicine, Polygonum capitatum *in vitro*. *Molecules*. 2014;19:10291-308.
53. Tang SC, **Chen Y\***. Novel Therapeutic Targets for Pancreatic Cancer. *World J Gastroenterol*. 2014;20:10825-10844.
54. Zhao J, Feng Y, Yan H, **Chen Y**, Wang J, Chua B, Miao J, Yin D.  $\beta$ -arrestin2/miR-155/GSK3 $\beta$  regulates transition of 5'-azacytidine-induced Sca-1-positive Cells to Cardiomyocytes. *J Cell Mol Med*. 2014;18:1562-70.

55. Lee KY, Chan KY, Tsang KS, **Chen Y**, Kung HF, Ng PC, Li CK, Leung KT, Li K. Ubiquitous Expression of MAKORIN-2 in Normal and Malignant Hematopoietic Cells and Its Growth Promoting Activity. *PLoS One*. 2014;9:e92706.
56. Xiao ZG, Chow SC, Li CH, Tang SC, Tsui SKW, Lin ZX, **Chen Y\***. Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma. *Eur J Pharmacol*. 2014;728:141-150.
57. Zhang Y, Liu J, Tian XY, Wong WT, **Chen Y**, Wang L, Luo J, Cheang WS, Lau CW, Kwan KM, Wang N, Yao X, Huang Y. Inhibition of Bone Morphogenic Protein 4 Restores Endothelial Function in db/db Diabetic Mice. *Arterioscler Thromb Vasc Biol*. 2014, 34:152-9.
58. Wang Y, Ma JY, Chow SC, Li CH, Xiao ZG, Feng R, Fu J, **Chen Y\***. A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2. *Tumor Biology*. 2014, 35:205-12.
59. Li CH, **Chen Y\***. Targeting long non-coding RNAs in cancer: progress and perspective. *Int J Biochem Cell Biol*. 2013, 45:1895-1910.
60. Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, **Chen Y\***. Enhancer of Zeste Homolog 2 Silences microRNA-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin. *Gastroenterology*. 2013, 144:1086-1097.
61. Fu J, Ma JY, Zhang XF, Wang Y, Feng R, **Chen Y\***, Tan XS, Zhang YY, Sun YP, Zhou Y, Ma C, He CY, Zhao ZX, Du XW. Identification of metabolites of FR429, a potential antitumor ellagitannin, transformed by rat intestinal bacteria *in vitro*, based on liquid Chromatography - ion trap - time of flight mass spectrometry analysis. *J Pharm Biomed Anal*. 2012, 71:162-7.
62. Fok KL, Chung CM, Yi SQ, Jiang X, Sun X, Chen H, **Chen Y**, Kung H, Tao Q, Diao R, Chan H, Zhang XH, Chung YW, Cai Z, Chan HC. STK31 maintains the undifferentiated state of colon cancer cells. *Carcinogenesis*. 2012;33:2044-53.
63. Wong CCM, Zhang L, Li ZJ, Wu WKK, Ren SX, **Chen Y**, Ng TB, Cho CH. Protective Effects of Cathelicidin-Encoding Lactococcus lactis in Murine Ulcerative Colitis. *J Gastroenterol Hepatol*. 2012, 27:1205-12.
64. Tian XY, Yung LH, Wong WT, Liu J, Leung FP, Liu L, **Chen Y**, Kong SK, Kwan KM, Ng SM, Lai PB, Yung LM, Yao X, Huang Y. Bone morphogenic protein-4 induces endothelial cell apoptosis through oxidative stress-dependent p38MAPK and JNK pathway. *J Mol Cell Cardiol*. 2012;52:237-44.
65. Yip WK, Cheng ASL, Zhu R, Lau SK, **Chen Y**, Sung JG, Lai PB, Ng EK, Yu J, Wong N, To KF, Wong WS, Sung JJY, Chan HLY. Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development. *PLoS One*. 2011;6:e22888.
66. Cheng ASL, Lau SS, **Chen Y**, Kondo Y, Li MS, Feng H, Ching AK, Cheung PK, Wong KH, Jin H, Choy R, Yu J, To KF, Wong N, Huang TH, Sung JJY. EZH2-mediated concordant repression of Wnt antagonists promotes  $\beta$ -catenin-dependent hepatocarcinogenesis. *Cancer Res*. 2011;71: 4028-4039.
67. Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, **Chen Y**, Wu QL, Liu YH, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. *Gut*. 2011; 60:967-76.
68. Yue Y, Jin F, Deng R, Cai J, **Chen Y**, Lin MC, Kung HF, Wu C. Revisit complexation between DNA and polyethylenimine-Effect of uncomplexed chains free in the solution mixture on gene transfection. *J Control Release*. 2011; 155:67-76.
69. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, **Chen Y**, Peng Y, Yao KT, Kung HF, Li

- XP. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. *Cancer Res.* 2011;71:225-33.
70. Lan FF, Wang H, **Chen Y**, Chan CY, Ng SS, Li K, Xie D, He ML, Lin MC, Kung HF. Has-let-7g inhibits proliferation of hepatocellular carcinoma cells by down-regulation of c-Mys and up-regulation of p16(INK4A). *Int J Cancer.* 2011; 128:319-31.
  71. Zhang J, He ML, Dong Q, Xie WD, **Chen Y**, Lin MC, Leung PC, Zhang YO, Kung HF. Aqueous extracts of Fructus Ligustri Lucidi enhance the sensitivity of human colorectal carcinoma DLD-1 cells to doxorubicin-induced apoptosis via TBX3 suppression. *Integr Cancer Ther.* 2011;10:85-91.
  72. Diao S, Zhang JF, Wang H, **Chen Y\***, Kung HF. Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma. *Proteomics.* 2010, 10:3723-31.
  73. Wong WT, Tian XY, **Chen Y**, Leung FP, Wong SL, Lee HK, Ng CF, Yao X, Vanhoutte, Tipoe G, Huang Y. COX-2 up-regulation and prostaglandin F2 $\alpha$  mediate bone morphogenic protein 4-induced endothelial dysfunction in hypertension. *Circ Res.* 2010, 107:984-991.
  74. Li XY, **Chen Y**, Zhou KY, Zhang MH, Luo HQ, Kung HF, Zhou X. Overexpression of Bax inhibitor-1 (BI-1) induces cell transformation in NIH3T3 cells. *Cell Biol Int.* 2010, 34:1099-104.
  75. Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, **Chen Y**, Guan XY, Zeng YX, Kung HF, Xie D. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. *Carcinogenesis.* 2010; 31:1576-83.
  76. **Chen Y**, Xie D, Li WY, Cheung CM, Yao H, Chan CY, Xu FP, Liu YH, Sung JJY, Kung HF. RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo, *Cancer Lett*, 2010, 297:109-16.
  77. An X, Ng SS, Xie D, Zeng YX, Sze J, Wang J, **Chen Y**, Chow BK, Lu G, Poon WS, Kung HF, Wong BC, Lin MC. Functional characterisation of cell cycle-related kinase (CCRK) in colorectal cancer carcinogenesis. *Eur J Cancer.* 2010, 46:1752- 61.
  78. Wu GQ, Liao YJ, Qin ZQ, He LR, **Chen Y**, Zeng YX, Kung HF, Xie D. PYRIN domain of NALP2 inhibits cell proliferation and tumor growth of human glioblastoma. *Plasmid.* 2010, 64:41-50.
  79. Hua WF, Fu YS, Liao YJ, Xia WJ, Chen Y, Zeng YX, Kung HF, Xie D. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. *Eur J Pharmacol.* 2010, 637:16-21.
  80. Jiang L, **Chen Y\***, Chan CY, Lu G, Wang H, Li JC, Kung HF. Dynamic transcriptional changes of TIEG1 and TIEG2 during mouse tissue development. *Anat Rec.* 2010, 293:858-64.
  81. He LR, Liu MZ, Li BK, Rao HL, Liao YJ, **Chen Y**, Guan XY, Zeng YX, Kung HF, Xie D. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. *Int J Cancer.* 2010, 127:138-47.
  82. Chen SC, Lu G, Chan CY, **Chen Y**, Yew DT, Feng ZT, Kung HF. Microarray profile of brain aging related genes in frontal cortex of SAMP8, *J Mol Neurosci.* 2010, 41: 12-6.
  83. Zhang JF, Li G, Chan CY, Meng CL, Lin MC, **Chen Y**, He ML, Leung PC, Kung HF. Flavonoids of Herba Epimedii regulate osteogenesis of human mesenchymal stem cells through BMP and Wnt/ $\beta$ -catenin signaling pathway. *Mol Cell Endocrinol.* 2010, 314:70-4.
  84. Ma Y, Yu J, Chan HL, **Chen Y**, Wang H, Chen Y, Chan CY, Go MY, Tsai SN, Ngai

- SM, To KF, Tong JH, He QY, Sung JJ, Kung HF, Cheng CH, He ML. Glucose-Regulated Protein 78 is an intracellular antiviral factor against Hepatitis B virus. *Mol Cell Proteomics*. 2009, 8:2582-94.
85. Li M, Wang J, Ng SS, Chan CY, He ML, Yu F, Lai L, Shi C, **Chen Y**, Yew DT, Kung HF, Lin MC. Adenosine diphosphate-ribosylation factor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation. *Cancer*. 2009,115:4959 -4972.
  86. Deng R, Yue Y, Jin F, **Chen Y**, Kung HF, Lin MC, Wu C. Revisit the complexation of PEI and DNA- How to make low cytotoxic and high efficient PEI gene transfection non-viral vectors with a controllable chain length and structure? *J Control Release*. 2009, 140:40-6.
  87. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Lee TK, Zhang C, Dai H, Wang XL, Ng IO, **Chen Y**, Kung HF, Lowe SW, Poon RT, Wang JH, Luk JM. Targeting Cadherin-17 Inactivates Wnt Signaling and Inhibits Tumor Growth in Liver Carcinoma, *Hepatology*. 2009, 50:1453-1463.
  88. Moorman J, Zhang Y, Liu B, Lesage G, **Chen Y**, Stuart C, Prayther D, Yin D. HIV-1 gp120 primes lymphocytes for opioid-induced, beta-arrestin 2-dependent apoptosis. *Biochim Biophys Acta*. 2009, 1793:1366-71.
  89. Liang B, He ML, Chan CY, **Chen Y**, Li XP, Li Y, Zheng D, Lin MC, Kung HF, Shuai XT, Peng Y. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat. *Biomaterials*. 2009, 30:4014-4020.
  90. Xia H, Qi Y, Ng SS, Chen X, Chen S, Ge R, Li G, **Chen Y**, He ML, Kung HF, Lai L, Lin MC. microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. *Brain Res*. 2009, 1269:158-165.
  91. Dong Q, Liu Z, **Chen Y**, Chan CY, Lin MC, Kung HF, Chan HL, Sung JJ, He ML. High Level Virion Production and Surface Antigen Expression with One and a Half Copies of Hepatitis B Viral Genome. *J Virol Methods*. 2009, 159: 135–140.
  92. Xia H, Qi Y, Ng SS, Chen X, Chen S, Fang M, Li D, Zhao Y, Ge R, Li G, **Chen Y**, He ML, Kung HF, Lai L, Lin MC. MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. *Biochem Biophys Res Commun*. 2009, 380: 205-10.
  93. Wang X, **Chen Y\***, Han QB, Chan CY, Wang H, Liu Z, Cheng CHK, Yew DT, Lin MC, He ML, Xu HX, Sung JJY, Kung HF. Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. *Proteomics*. 2009, 9:242–253.
  94. Jiang L, **Chen Y\***, Chan CY, Wang X, Lin L, He ML, Lin M, Yew D, Sung JJY, Li JC, Kung HF. Down-regulation of stathmin is required for TGF- $\beta$  inducible early gene 1 induced growth inhibition of pancreatic cancer cells. *Cancer Lett*. 2009; 274:101-108.
  95. Zhang B, Bai YX, Ma HH, Wang ZW, Huang PT, Huang CF, Peng Y, **Chen Y**, Kung HF, Huang JJ. Silencing PinX1 compromises Telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. *Cancer Res*. 2009, 69: 1-9.
  96. Li Z, He ML, Yao H, Dong Q, **Chen Y**, Chan CY, Zheng BJ, Yuen KY, Peng Y, Sun Q, Yang X, Lin MC, Sung JJY, Kung HF. Inhibition of HBV replication and gene expression in vitro and in vivo with a single AAV vector delivering two shRNA molecules. *BMB Rep*. 2009, 42:59-64.
  97. Li Z, Yao H, Ma Y, Dong QM, **Chen Y**, Peng Y, Zheng B, Huang JD, Chan CCY, Lin MC, Sung JJ, Yuen KY, Kung HF, He ML. Inhibition of HBV gene expression and replication by stably expressed interferon- $\alpha$ 1 via adeno-associated viral vectors. *J Gene Med*. 2008, 10: 619-627.

98. Dong Q, Chan HLY, Liu Z, Chan DP, Zhang B, **Chen Y**, Kung HF, Sung JJY, He ML. A1762T/G1764A Mutations of Hepatitis B virus, Associated with the Increased Risk of Hepatocellular Carcinoma, Reduce Basal Core Promoter Activities. *Biochem Biophys Res Commun*. 2008, 374:773-776.
99. **Chen Y**, Cheung YT, Kong LD, Ng TB, Qiao CF, Mo SF, Xu HX, Kung HF. Transcriptional regulation of Corticotropin-Releasing-Factor gene by Furocoumarins isolated from Seeds of Psorales Corylifolia. *Life Sci*. 2008, 82:1117-1121.
100. **Chen Y**, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, Hui CK, Lau GK, He ML, Sung J, Kung HF. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. *Hepatology*. 2007,46:200-208.
100. Ng SS, Gao Y, Chau DH, Li GH, Lai L, Huang PT, Huang C, Huang JJ, **Chen Y**, Kung HF, Lin MC. A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. *Cancer Gene Ther*. 2007, 14: 561- 572.
101. **Chen Y**, Lin MC, Wang H, Chan CY, Jiang L, Ngai SM, Yu J, He ML, Shaw PC, Yew DT, Sung JJ, Kung HF. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. *Proteomics*. 2007, 7:3097-3104.
102. Ng SS, Cheung YT, An XM, **Chen Y**, Li M, Li G, Cheung W, Sze J, Lai L, He ML, Peng Y, Xia H, Wong BCY, Leung SY, Kung HF, Lin MC. Cell cycle related kinase (CCRK): a novel candidate oncogene in human glioblastoma. *J Natl Cancer Inst*. 2007, 99: 936- 948.
103. **Chen Y**, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible expression of siRNAs inhibited breast cancer cell invasion *in vitro*. *Cancer Res*. 2003, 63:4801-4804.
102. Song CZ, Keller K, **Chen Y**, Stamatoyannopoulos G. Functional interplay between CBP and PCAF in acetylation and regulation of transcription factor KLF13 activity. *J Mol Biol*. 2003, 329:207-215.
103. Song CZ, Keller K, **Chen Y**, Murata K, Stamatoyannopoulos G. Transcription coactivator CBP has direct DNA binding activity and stimulates transcription factor DNA binding through small domain. *Biochem Biophys Res Commun*, 2002, 296:118 -124
104. **Chen Y**, Song C, Luo CQ. Short hairpin RNAs induced RNA interference in human cells, *Chinese Journal of Cancer*. 2003, 22:566-570.
105. **Chen Y**, Zhou M, Zhang Y, Zhou K. Cisplatin induced apoptosis in nasopharyngeal cancer cells and decrease membrane potential. *Chinese Journal of Cancer*. 2001,20:887-888.
106. **Chen Y**, Zhang Y, Zhou K. Preliminary studies of apoptosis in human nasopharyngeal carcinoma CNE-2Z cells induced by arsenic trioxide and its mechanism, *Chinese Journal of Cancer*. 2001, 20: 61-65.
107. Zhang Y, **Chen Y**, Zhou K, Cai K, Liang T. bcl-xS mediated sensitization of human nasopharyngeal carcinoma cells to camptothecin-induced apoptosis, *Chin Arch Otolaryngeal Head Neck Surg*. 2001,8:114-117.
108. Zhang Y, **Chen Y**, Zhou K, Cai K. Mitochondrial mechanisms of CPT-induced apoptosis in nasopharyngeal carcinoma cells, *J Clinical Otorhinolaryngology*. 2001, 15: 309- 311.
109. Zhang Y, **Chen Y**, Zhou K, Liang T. Bcl-xS promotes arsenic trioxide-induced apoptosis in nasopharyngeal carcinoma cells, *Chin J Otorhinolaryngology- Skull Base Surgery*. 2001,7:95-97.
110. Xie T, Tang D, **Chen Y**, Liu CQ, Zhou K. Clinical characteristics of angiotension

converting enzyme gene polymorphism in chronic glomerulonephritis and primary nephrotic syndrome. *Guangdong Medical Journal*. 2001, 22: 11-12.

111. **Chen Y**, Zhang Y, Zhou K, Ling G. GFP used as a reporter gene for optimizing lipofection. *J Guangdong Medical College*, 2001, 3: 28-29

112. **Chen Y**, Zhang Y, Zhou K, Ling G. Transcription and expression of bcl-x gene in two cell lines of nasopharyngeal carcinoma. *Academic Journal of Guangdong Medical College*, 2001, 1:8-9.

113. **Chen Y**, Zhang Y, Zhou K, Zhou M, Liang T. Bcl-xS gene sensitizes nasopharyngeal carcinoma cells to cisplatin-induced apoptosis, *Chin J Cancer Biother*, 2000, 8: 84- 87.

114. **Chen Y**, Zhou K. Bcl-x gene and its regulation on apoptosis, *Prog Biochem Biophys*, 1999, 26: 534-537.

### Book chapters

1. **Chen Y**, Li CH. Novel therapeutic targets for hepatocellular carcinoma treatment. In: Lau WY, editors: *Hepatocellular Carcinoma-Basic Research*, 02,2012, pp35-60; InTech.
2. Li CH, **Chen Y**, Insight Into the Role of Long Noncoding RNA in Cancer Development and Progression. In: Kwang Jeon, editors: *International Review of Cell and Molecular Biology*, Vol 326, Chennai: Academic Press; 2016, p. 33-66.

### Patents

1. **Chen Y**. Small molecule modulators of microRNA-34a, US10,865,176 B2, Date of Patent Dec.15.2020.
2. **Chen Y**. Small molecule modulators of microRNA-34a, Chinese patent ZL 201310718172.8, Date of Patent Jan.4. 2017.
3. Anti-inflammation bacteria, Chinese patent approved.

### Invited and Oral Presentations

1. **Chen Y**. CircFOXK2 Promotes Tumor Growth and Metastasis of Pancreatic Ductal Adenocarcinoma via Complexing with RNA Binding Proteins and Sponging MiR-942. Conference: The 52<sup>th</sup> Meeting of the European Pancreatic Club. Location: Virtual Meeting. Dates: Jul 2-3, 2020. Sponsor(s): European Pancreatic Club.
2. **Chen Y**. Targeting Non-coding RNAs for Cancer Therapy. Conference: Pharma R&D 2020. Location: Los Angeles, CA. Dates: Feb 24-26, 2020. Sponsor(s): United Scientific Group.
3. **Chen Y**. Epigenetic regulation of short and long non-coding RNAs in cancer. Conference: The 1<sup>st</sup> Annual International Congress of Cancer & Clinical Oncology. Location: Singapore. Dates: Dec 5, 2019.
4. **Chen Y**. Epigenetic regulation of small and long non-coding RNAs in gastrointestinal cancer. Conference: Shenzhen Gastrointestinal Oncology Meeting. Location: Shenzhen, China. Dates: Nov 29-30, 2019. Sponsor(s): Shenzhen University.
5. **Chen Y**. Epigenetic regulation of small and long non-coding RNAs in gastrointestinal cancer. Conference: The 4<sup>th</sup> Int'l Conference on Gastroenterology and Hepatology. Location: Guilin, China. Dates: Nov 22-24, 2019. Sponsor(s): Engii Conference.
6. **Chen Y**. circRNAs in gastrointestinal cancer. Conference: Shenzhen Digestive Cancer Meeting. Location: Shenzhen, China. Dates: Nov 2, 2019. Sponsor(s): Shenzhen Anti-cancer Association.
7. **Chen Y**. Epigenetic regulation of small and long non-coding RNAs in GI cancer. Invited by The 7<sup>th</sup> Affiliated Hospital of Sun Yat-sen University, Location: Shenzhen. Dates: Sep

- 16, 2019.
8. **Chen Y.** circFOXK2 promotes tumor growth and metastasis of pancreatic ductal adenocarcinoma via complexing with YBX1 and hnRNPK. Conference: The 5<sup>th</sup> Circular RNA Meeting. Location: Guangzhou, China. Dates: Aug 4-6, 2019. Sponsor(s): Guangzhou Science Park.
  9. **Chen Y.** Targeting non-coding RNAs for cancer therapy. Conference: The 17<sup>th</sup> Annual Congress of International Drug Discovery Science & Technology-2019. Location: Kyoto, Japan. Dates: Jul 25-27, 2019. Sponsor(s): BIT Life Science.
  10. **Chen Y.** Novel therapeutic targets for cancer immunotherapy. Conference: Great Bay Area Lung Cancer Meeting. Location: Guangzhou, China. Dates: Jul 12-13, 2019. Sponsor(s): Guangzhou Medical University.
  11. **Chen Y.** Epigenetic Regulation of Short and Long ncRNAs in Cancer. Conference: The 10th Annual World DNA and Genome Day-2019. Location; Nanjing, China. Dates: Apr 24-26, 2019.
  12. **Chen Y.** Identification of personalized medicine biomarker for pancreatic cancer. Conference: Translational Medicine in Oncology. Location: Shanghai, China. Dates: Aug 24-26, 2018. Sponsor(s): Bioon.
  13. **Chen Y.** Translational medicine in pancreatic cancer. Conference: The 2018 Annual Meeting of the National Pancreas Diseases Committee of China. Location: Guangzhou, China. Dates: Aug 3-4, 2018. Sponsor(s): National Pancreas Diseases Committee of China.
  14. **Chen Y.** Identification of critical cirRNAs in pancreatic cancer. Conference: The 4<sup>th</sup> Circular RNA Meeting. Dates: Jul 6-8, 2018. Location: Guangzhou, China. Sponsor(s): Guangzhou Science Park.
  15. **Chen Y.** Novel therapeutic targets for pancreatic cancer. Conference: 2018 Annual Meeting of Hong Kong Society of Cell Biology. Dates: Jul 4, 2018. Location; Hong Kong. Sponsor(s): Hong Kong Society of Cell Biology.
  16. **Chen Y.** Novel therapeutic targets for pancreatic cancer. Conference: 2018 Annual Meeting of the Chinese Traditional Chinese Medicine Oncology Association. Dates: May 26-27, 2018. Location: Guangzhou, China. Sponsor(s): Guangzhou University of Chinese Medicine.
  17. **Chen Y.** Personalized medicine in pancreatic cancer. Conference: Shenzhen Gastro-intestinal Oncology Meeting. Location: Shenzhen, China. Dates: Nov 17-18, 2017. Sponsor(s): Shenzhen Baoan Hospital.
  18. **Chen Y.** Targeting microRNAs for cancer therapy. Conference: The 2017 International Young Scientists in Life Science Forum. Location: Beijing, China. Dates: Nov 11-12, 2017. Sponsor(s): Beijing Economic Development Zone.
  19. **Chen Y.** Genomics of pancreatic cancer and perspective of personalized medicine based on gene expression. Conference: The 2<sup>nd</sup> Shanghai International Gastro-intestinal Oncology Meeting. Location: Shanghai, China. Dates: Nov 3-5, 2017. Sponsor(s): Shanghai Changhai Hospital.
  20. **Chen Y.** Novel therapeutic targets of pancreatic cancer. Conference: The 3<sup>rd</sup> Sino-Europe Pancrease Disease Conference. Location: Zhuzhou, China. Dates: Oct 13-15, 2017. Sponsor(s): Central South University.
  21. **Chen Y.** Progress in the basic research of pancreatic cancer. Conference: The 8<sup>th</sup> Lingnan International Pancreatic Surgery Summit. Location; Guangzhou, China. Dates: Sep 9-10, 2017. Sponsor(s): Guangdong Anti-cancer Association.
  22. **Chen Y.** Novel therapeutic targets for pancreatic cancer. Conference: 2017 Hong Kong Academic Summit of Clinical Oncology. Location: Hong Kong. Dates: Jul 22, 2017. Sponsor(s): Hong Kong Academy of Medical Sciences.

23. **Chen Y.** The small and long non-coding RNAs in pancreatic cancer. Conference: The 11<sup>th</sup> Shenzhen Hapato-biliary Surgery Forum. Location: Shenzhen, China. Dates: Jun 30-31, 2017. Sponsor(s): Shenzhen Bao-An Hospital.
24. **Chen Y.** A small molecule modulator of microrNA-34a with anti-cancer activity. Conference: ChinaBio Partnering Forum 2017. Location; Zhuhai, China. Dates: May 31, 2017. Sponsor(s): ChinaBio Group.
25. **Chen Y.** Precision medicine of pancreatic cancer. Conference: Shenzhen TCM Surgery Forum. Location: Shenzhen, China. Dates: Apr 28-29, 2017. Sponsor(s): Shenzhen TCM Hospital.
26. **Chen Y.** Non-coding RNAs in pancreatic cancer. Invited by Shenzhen University. Dates: Mar 28, 2017.
27. **Chen Y.** Epigenetic regulation of non-coding RNAs in cancer and its therapeutic implication. Invited by Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College. Location: Chengdu, China. Dates: Dec 12-14, 2016.
28. **Chen Y.** Development of novel anti-cancer drugs by targeting microRNAs. Conference: 2016 Innovative Drug Development & Application Conference. Location: Sanya, China. Dates: Dec 1-3, 2016. Sponsor(s): Thousand Talent Magazine.
29. **Chen Y.** A novel small molecule with anti-cancer activities. Conference: The 2<sup>nd</sup> Int'l Conference on Gastroenterology and Hepatology. Location: Sanya, China. Dates: Dec 1-3, 2016. Sponsor(s): Engii Conference.
30. **Chen Y.** Novel therapeutic targets for pancreatic cancer. Conference: The 10<sup>th</sup> Shenzhen General Surgery Forum. Location: Shenzhen, China. Dates: Oct 14-15. Location: Shenzhen, China. Dates: Dec 1-3, 2016. Sponsor(s): Shenzhen Bao-An Hospital.
31. **Chen Y.** Identification of novel therapeutic targets for pancreatic cancer. Conference: Pancreatic Cancer Multi-Disiplinary Treatment (MDT) Conference. Dates: Sep 11, 2016. Location: Guangzhou, China. Sponsor(s): Guangdong Anti-Cancer Association.
32. **Chen Y.** Novel therapeutic targets for pancreatic duct adenocarcinoma. Conference: The 10<sup>th</sup> Annual Meeting of Pancreatic Cancer Committee, Chinese Anti-cancer Association. Location: Shanghai, China, Dates: Jul 15-16, 2016. Sponsor(s): Fudan University.
33. **Chen Y.** Anti-cancer efficacy of a small molecule modulator of microRNA-34a. Conference: Bio-Forum 2016. Location: Shanghai, China. Dates: Jun 22-25, 2016. Sponsor(s): Shanghai Centre of Biomedicine Development.
34. **Chen Y.** A novel anti-cancer small molecule. Conference: Innovative Drug Development & Cooperation Summit. Location: Hangzhou, China. Dates: May 19-22, 2016. Sponsor(s): Bioon.
35. **Chen Y.** Novel therapeutic targets for pancreatic cancer. Invited by Xiangya Hospital, Central South University, Changsha, China. Dates: Mar 6, 2016.
36. **Chen Y.** EZH2 regulation of microRNA expression in pancreatic ductal adenocarcinoma cells and its therapeutic implication. Conference: The 19<sup>th</sup> International Association of Pancreatology Annual Meeting. Location: Shanghai, China. Dates: Aug 27-29, 2015. Sponsor(s): International Association of Pancreatology.
37. **Chen Y.** Potential of Non-coding RNAs as diagnostic biomarkers for cancer. Conference: The annual meeting of Foshan Medical Association. Location: Foshan, China. Dates: Jun 25, 2015. Sponsor(s): Foshan Medical Association.
38. **Chen Y.** Application of non-coding RNAs in cancer diagnosis. Conference: World

in vitro diagnostic conference 2015. Location; Beijing, China. Dates: Jun 4-5, 2015. Sponsor(s): Influnce.

39. **Chen Y.** Non-coding RNAs in pancreatic cancer. Conference: The 2<sup>nd</sup> Sino-Europe Pancreas Disease Conference. Location; Changsha, China. Dates: May 29-31, 2015. Sponsor(s): Central South University.
40. **Chen Y.** The anticancer efficacy of the small molecule modulator of tumor suppressor microRNA-34a. Conference: The 2015 Frontier Forum Medical Sciences & The 14<sup>th</sup> National Meeting on Tumor Pharmacology and Chemotherapy. Location: Shenyang, China. Dates: Apr 24-27, 2015. Sponsor(s): Chinese Anticancer Association.
41. **Chen Y.** Epigenetic regulation of microRNAs in cancer and its therapeutic implication. Conference: Regional and Targeted Therapy for Cancer Meeting. Location: Shanghai, China. Dates: Nov 14-16, 2014. Sponsor(s): Fudan University.

### Conference Organization

1. Technical Program Committee Member, The Fifth International Conference on Biological Information and Biomedical Engineering (BIBE 2021), to be held during July 20-22, 2021 in Hangzhou, China.
2. Organizing Committee Member, Annual Meeting on Cancer Research (Cancer Conference 2020) during 26-27 October, 2020 at Dubai, UAE.
3. Organizing Committee Member, The fourth International Cancer Conference and Expo, September 16-18, 2020 at Baltimore, USA.
4. Organizing Committee Member, European Conference on Oncology & Cancer Therapy (Virtual) during September 07-08, 2020.
5. Organizing Committee Member, The fifth World Congress On Cancer and Diagnostics, June 15-16, 2020, Berlin, Germany.
6. Programme Committee Member & Session Chair, The 5<sup>th</sup> Int'l Conference on Gastroenterology and Hepatology (ICGEH 2019), Nov 22-24, 2019, Guilin, China.
7. Organizing Committee Member, Shenzhen Digestive Cancer Meeting, Nov 2, 2019.
8. Organizing Committee Member, 1<sup>st</sup> International Meeting on Biomedical engineering during October 14-15, 2019 at Dubai, UAE.
9. Organizing Committee Member & Session Chair, The 5<sup>th</sup> Circular RNA Meeting, Aug 4-6, 2019, Guangzhou, China.
10. Technical Program Committee Member, 34<sup>th</sup> Euro-Global Summit on Cancer Therapy & Radiation Oncology (Euro Cancer 2019), July 25-27, 2019 at London, UK.
11. Technical Program Committee Member, The Third International Conference on Biological Information and Biomedical Engineering (BIBE2019), July 16-18, 2019, Hangzhou, China.
12. Organizing Committee Member & Session Chair, The 4<sup>th</sup> Circular RNA Meeting, Jul 6-8, 2018, Guangzhou, China.
13. Organizing Committee Member, Shenzhen Gastro-intestinal Oncology Meeting, Nov 17-18, 2017, Shenzhen, China.
14. Technical Program Committee Member, The 2017 International Conference on Medicine Sciences and Bioengineering (ICMSB2017), Nov 17-19, 2017, Chengdu, China.
15. Programme Committee Member, The 3<sup>rd</sup> Sino-Europe Pancreas Diseases Conference, Oct 15-16, 2017, Zhuzhou, China.
16. Organizing Committee Member, 11<sup>th</sup> Shenzhen Hapato-billiary Surgery Forum, Jun 30-31, 2017, Shenzhen, China.
17. Programme Committee Member, The 2<sup>nd</sup> Int'l Conference on Gastroenterology and

Hepatology (ICGEH 2016), Dec 3-5, 2016, Sanya, China.

18. Programme Committee Member, The 2016 International Conference on Medicine Sciences and Bioengineering, Oct 15-16, 2016, Guangzhou, China.
19. Organizing Committee Member, 10<sup>th</sup> Shenzhen General Surgery Forum, Oct 14-15, 2016, Shenzhen, China.
20. Programme Committee Member, The 2nd Sino-Europe Pancreas Disease Conference, May 29-31, 2015, Changsha, China.
21. Session Co-chair, The 2015 Frontier Forum Medical Sciences & The 14th National Meeting on Tumor Pharmacology and Chemotherapy, Apr 24-27, 2015, Shenyang, China.